Fmr LLC Cara Therapeutics, Inc. Transaction History

Fmr LLC

$1.52 Trillion
Q2 2024

A detailed history of Fmr LLC transactions in Cara Therapeutics, Inc. stock. As of the latest transaction made, Fmr LLC holds 177,523 shares of CARA stock, worth $53,256. This represents 0.0% of its overall portfolio holdings.

Number of Shares

177,523

Previous 162,135 9.49%

Holding current value

$53,256

Previous $147,000 68.71%

% of portfolio

0.0%

Previous 0.0%

13 transactions

Quarter	Operation	Price Per share	shares change	shares Held
Q2 2024 Aug 13, 2024	BUY	$0.24 - $0.92 $3,693 - $14,156	15,388 Added 9.49%	177,523 $46,000
Q1 2024 May 13, 2024	BUY	$0.52 - $1.05 $2,506 - $5,062	4,821 Added 3.06%	162,135 $147,000
Q4 2023 Feb 13, 2024	SELL	$0.6 - $1.65 $3,513 - $9,660	-5,855 Reduced 3.59%	157,314 $116,000
Q3 2023 Nov 13, 2023	BUY	$1.67 - $3.33 $18,097 - $36,087	10,837 Added 7.11%	163,169 $274,000
Q2 2023 Aug 11, 2023	BUY	$2.83 - $4.94 $426,599 - $744,665	150,742 Added 9480.63%	152,332 $431,000
Q1 2023 May 11, 2023	SELL	$4.89 - $12.27 $1,427 - $3,582	-292 Reduced 15.52%	1,590 $7,000
Q4 2022 Feb 13, 2023	BUY	$8.88 - $12.77 $10,815 - $15,553	1,218 Added 183.43%	1,882 $20,000
Q3 2022 Nov 10, 2022	SELL	$8.24 - $12.56 $7,836 - $11,944	-951 Reduced 58.89%	664 $6,000
Q2 2022 Aug 12, 2022	SELL	$7.45 - $13.84 $430,811 - $800,325	-57,827 Reduced 97.28%	1,615 $15,000
Q1 2022 May 13, 2022	BUY	$9.94 - $12.65 $590,436 - $751,410	59,400 Added 141428.56%	59,442 $722,000
Q4 2021 Feb 14, 2022	SELL	$11.99 - $18.14 $2,398 - $3,628	-200 Reduced 82.64%	42 $1,000
Q3 2021 Nov 15, 2021	SELL	$11.55 - $16.06 $161 - $224	-14 Reduced 5.47%	242 $3,000
Q2 2021 Aug 13, 2021	BUY	$12.38 - $29.19 $3,169 - $7,472	256 New	256 $3,000

Others Institutions Holding CARA

# of Institutions

Shares Held

16.4M

Call Options Held

55K

Put Options Held

500

View Full List

About Cara Therapeutics, Inc.

Ticker CARA
Exchange NASDAQ
Sector Healthcare
Industry Biotechnology
Shares Outstandng 53,725,900
Market Cap $16.1M
Description
Cara Therapeutics, Inc., an early commercial-stage biopharmaceutical company, focuses on developing and commercializing chemical entities with a primary focus on pruritus and pain by selectively targeting kappa opioid receptors in the United States. The company is developing product candidates that target the body's peripheral nervous system and...

More about CARA

Track This Portfolio

Portfolio Update

Get notified when there are updates to the investment portfolio of Fmr LLC, based on Form 13F filings with the SEC.

News

Stay updated on Fmr LLC with notifications on news.

Account